Chinese contract research organization GemPharmatech has expanded its presence in the United States with a new facility in San Diego, announced on April 17. The facility is designed for laboratories and housing genetically engineered mouse models, aimed at enhancing their capabilities in offering
With over 300 million people globally suffering from chronic hepatitis B, the disease presents a monumental challenge in the realm of public health. Traditional treatments have mainly focused on suppressing the virus rather than providing a cure, demanding lifelong therapy for many patients.
Allogene Therapeutics, a clinical-stage biotechnology company based in South San Francisco, has achieved a groundbreaking milestone. Their investigational product, ALLO-329, has received three Fast Track Designations (FTDs) from the FDA, marking a significant advancement in the treatment of
Glycomine, a leading biotechnology company based in San Francisco, has achieved a notable milestone by raising $115 million in funding for their pioneering project, GLM101. This development is particularly significant in an economic environment where securing substantial capital remains
Metastatic breast cancer remains one of the most challenging forms of cancer to treat, with only about one-third of patients surviving beyond five years post-diagnosis. Traditional treatments such as chemotherapy, radiation, and surgery have shown limited effectiveness, often accompanied by
The evolution of precision medicine is transforming the landscape of rare disease care, offering new hope through advanced diagnostic and treatment strategies. With the advent of genomic sequencing, patients and families are experiencing a shift from despair to optimism as they navigate complex
